Talquetamab (Talvey) plus daratumumab (Darzalex) with or without pomalidomide (Pomalyst) significantly improved survival outcomes over an active regimen for relapsed or refractory multiple myeloma, a phase III trial showed.
Among patients who had previously received at least one line of therapy, estimated 24-month progression-free survival (PFS) rates reached 81.3% with talquetamab plus daratumumab and pomalidomide and 77.6% with talquetamab plus daratumumab compared with 51.2% with daratumumab plus pomalidomide and dexamethasone, reported Peter M. Voorhees, MD, of Wake Forest University School of Medicine in Charlotte, North Carolina, and colleagues.
This translated into a 72% reduction in the risk of disease progression or death with talquetamab plus daratumumab and pomalidomide (HR 0.28, 95% CI 0.20-0.40, P<0.001), and a 67% reduction with talquetamab plus daratumumab (HR 0.33, 95% CI 0.24-0.46, P<0.001), versus daratumumab plus pomalidomide and dexamethasone.
Results from the MonumenTAL-3 trial were reported at the European Hematology Association annual congress in Stockholm and published in the New England Journal of Medicine.
Overall survival rates at 24 months were 89.2% with talquetamab plus daratumumab and pomalidomide and 87.9% with talquetamab plus daratumumab versus 79.1% with daratumumab plus pomalidomide and dexamethasone (HR 0.47, 95% CI 0.30-0.73 and HR 0.51, 95% CI 0.33-0.78, respectively).
